Shire Q4 top line up 9%; non-GAAP earnings/ADS up 13%; cash flow from operations down 70%; shares up 3% premarket

• Shire plc (NASDAQ:SHPG) Q4 results ($M): Total Revenues: 1,715.7 (+8.9%); Product Sales: 1,623.7 (+8.2%).
• Key Product Sales: Vyvanse: 453.3 (+18.2%); Lialda/Mezavant: 201.4 (+9.0%); Elaprase: 147.1 (+2.7%); Cinryze: 143.3 (+0.6%), Firazyr: 125.2 (+22.9%).
• Net Income: 280.6 (-87.1%); Non-GAAP Net Income: 587.6 (+13.2%); EPS: 0.473 (-87.1%); Earnings per ADS: 0.1419 (-87.1%); Non-GAAP Earnings per ADS: 0.2971 (+12.8%); CF Ops: 761.8 (-70.2%).
• 2016 Guidance: Product Sales Growth: 11 - 14%; Non-GAAP Earnings/ADS Growth: 7 - 10%.
• Shares are up 3% premarket on increased volume.